About Sagimet Biosciences Inc.
https://sagimet.comSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne.
CEO
David A. Happel
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 26
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
WOODLINE PARTNERS LP
Shares:1.5M
Value:$9.56M
BLUE OWL CAPITAL HOLDINGS LP
Shares:1.33M
Value:$8.46M
VANGUARD GROUP INC
Shares:1.2M
Value:$7.66M
Summary
Showing Top 3 of 76
About Sagimet Biosciences Inc.
https://sagimet.comSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $14.33M ▲ | $-12.91M ▼ | 0% | $-0.4 ▼ | $-12.91M ▼ |
| Q2-2025 | $0 | $11.93M ▼ | $-10.39M ▲ | 0% | $-0.32 ▲ | $-11.93M ▲ |
| Q1-2025 | $0 | $19.86M ▲ | $-18.18M ▼ | 0% | $-0.56 ▼ | $-19.86M ▼ |
| Q4-2024 | $0 | $18.2M ▲ | $-16.2M ▼ | 0% | $-0.5 ▼ | $-16.2M ▲ |
| Q3-2024 | $0 | $16.9M | $-14.62M | 0% | $-0.45 | $-16.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $116.69M ▼ | $128.4M ▼ | $9.15M ▲ | $119.25M ▼ |
| Q2-2025 | $125.41M ▼ | $137.41M ▼ | $7.25M ▲ | $130.16M ▼ |
| Q1-2025 | $144.57M ▼ | $146.17M ▼ | $7.18M ▲ | $138.99M ▼ |
| Q4-2024 | $151.25M ▼ | $160.26M ▼ | $4.45M ▲ | $155.81M ▼ |
| Q3-2024 | $152.49M | $174.78M | $4.09M | $170.68M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-12.91M ▼ | $-10.18M ▼ | $75K ▲ | $274K ▲ | $-9.83M ▲ | $-10.18M ▼ |
| Q2-2025 | $-10.39M ▲ | $-9.1M ▲ | $-13.29M ▼ | $1K ▲ | $-22.39M ▼ | $-9.1M ▲ |
| Q1-2025 | $-18.18M ▼ | $-14.54M ▼ | $3.41M ▼ | $0 | $-11.12M ▼ | $-14.54M ▼ |
| Q4-2024 | $-16.2M ▼ | $-11.02M ▲ | $9.85M ▲ | $0 | $-1.17M ▲ | $-11.02M ▲ |
| Q3-2024 | $-14.62M | $-19.57M | $624K | $0 | $-18.95M | $-19.57M |
CEO
David A. Happel
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 26
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
WOODLINE PARTNERS LP
Shares:1.5M
Value:$9.56M
BLUE OWL CAPITAL HOLDINGS LP
Shares:1.33M
Value:$8.46M
VANGUARD GROUP INC
Shares:1.2M
Value:$7.66M
Summary
Showing Top 3 of 76